SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent drug candidate to treat retinitis pigmentosa, the most common inherited retinal degeneration.

Biotechnology

SparingVision

Stéphane Boissel

Marie Uguen

Ryan Klimczak

Hélène Grimm

Mehdi Gasmi

Florence Paliargues

Anne-Sophie Gautron

Dan Chung

Rajiv Gangurde

Stanislas Piot

Florence Lorget

Clinical Advisory and Project Management

Finance and Corporate Development

Scientific Advisors

Leadership Team

Regulatory and Quality Assurance

Teams at SparingVision

Clinical Advisory and Project Management

Finance and Corporate Development

Scientific Advisors

Leadership Team

Regulatory and Quality Assurance